Immune cell therapy for hepatocellular carcinoma

Journal of Hematology & Oncology

卷:12

Eishiro Mizukoshi¹  Shuichi Kaneko¹ 

[1] Department of Gastroenterology, Graduate School of Medicine, Kanazawa University;

关键词: T cell;    Dendritic cell;    Chimeric antigen receptor;    Cytokine-induced killer cell;    Natural killer cell;    Immunotherapy;   

DOI  :  10.1186/s13045-019-0742-5

来源: DOAJ

【 摘 要 】

Abstract Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy. As a result, there have been numerous advancements in immune cell therapy using human immune cells. However, recent evidence suggests that one type of immunotherapy alone is not effective for the treatment of cancer, particularly solid tumors. Thus, effective immunotherapy combinations, such as the combination of checkpoint inhibitors and immune cell therapy, are needed. This review focuses on hepatocellular carcinoma among other solid tumors and discusses the current status and future of immune cell therapy in cancer immunotherapy.

【 授权许可】

Unknown